
RXRX vs LYCA
$RXRX vs $LYCA head to head: price, market cap, valuation, dividend, free float, relative volume and how actively each trades. The bigger value in the size rows is bolded. Tap either ticker for its live chart, full ownership breakdown and real-time alerts.
RXRX vs LYCA: the quick read
- ·RXRX is the larger company by market cap ($1.76B vs $1.63B).
- ·RXRX has been more active on our scanner (323 vs 156 alerts in 30 days).
- ·LYCA has the smaller float (47.9M vs 593.1M), which tends to mean sharper, more volatile moves.
- ·These sit in different industries (BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) vs Biological Products, (No Diagnostic Substances)), so they answer to different catalysts and a move in one says little about the other.
- ·They trade in different worlds by share price: RXRX is a low-priced stock where a few cents is a real percentage move, while the other is priced for steadier increments.
- ·Both stay busy on our scanner, 323 and 156 unusual-volume alerts over 30 days, so neither is the quiet one here.
- ·They are closely matched in size, within 8% of each other on market cap, which makes the rest of this table the interesting part.
- ·They have diverged badly over the year: LYCA is near the top of its 52-week range while RXRX is near the bottom of its own.
- ·They are pulling apart today: LYCA is outperforming the other by roughly 8.6 percentage points on the session.
Objective differences only. Not investment advice.
Watching RXRX or LYCA? Get each morning’s movers by email
Free daily email of the top plays and unusual-volume alerts our scanner flags. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Frequently asked questions
Everything you need to know comparing RXRX and LYCA on TheDesperateTrader.
- Is RXRX or LYCA the better stock?
- "Better" depends on your goal, and these two are not alike. RXRX is the larger company by market cap ($1.76B vs $1.63B). RXRX has been more active on our scanner (323 vs 156 alerts in 30 days). LYCA has the smaller float (47.9M vs 593.1M), which tends to mean sharper, more volatile moves. Those are the measured differences, not a recommendation, and nothing here is investment advice.
- What is the difference between RXRX and LYCA?
- The differences that matter: they are not in the same business - RXRX is biological products, (no diagnostic substances) and LYCA is biological products, (no diagnostic substances); they are similar in size ($1.76B vs $1.63B); they trade at very different share prices ($2.67 vs $32.26); RXRX sits at 6% of its 52-week range against 87% for LYCA; our scanner flagged RXRX 323 times in the last 30 days against 156 for LYCA. Everything above is measured from the latest completed session and SEC filings.
- Which of RXRX and LYCA is more active right now?
- Right now RXRX is at about 1.5x its normal volume and LYCA is at about 1.1x, so RXRX is the one drawing unusual attention today. Relative volume (RVOL) compares a stock's volume to its own recent average, so it reads the same way for a megacap and a microcap and is the quickest way to tell which of two similar names is actually in play.
- Is this comparison data live?
- Prices and % changes are anchored to the latest completed session and split-adjusted, so a reverse split never shows as a fake move. Float is estimated from SEC filings and refreshed as new filings publish.
Trading RXRX or LYCA? Get real-time unusual-volume alerts the moment either one moves, free.
No card · 5 premium daysMore RXRX and LYCA comparisons
Same sector, similar size. These are the peers each one is usually weighed against.
Explore the market
Free, live market tools. No account required to look.